NEW YORK (GenomeWeb News) – Cancer care firm N-of-One today announced a deal with Foundation Medicine to translate sequencing data into clinically relevant information.

Under the terms of the agreement, Foundation will identify potential biomarkers using its sequencing and analytic capabilities on patient tumor samples. N-of-One will then use its PrecisionWorks platform to translate data from Foundation to link molecular changes with current information about relevant target therapies and clinical trials that may be used to guide treatment.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.